Worldwide Healthcare Trust’s best drug stocks

TL;DR

Worldwide Healthcare Trust, with a successful track record, attributes its outperformance to a global approach, diverse investment options, deep industry expertise, and a large investment team.

Transcript

hello with me today i have sven borrow co-manager of the worldwide healthcare trust first of all sven happy birthday to the trust which is 25 years old this year your investment approach which is very much about identifying sources of outperformance with a focus on fundamental research it served you well in that time how do you explain to viewers h... Read More

Key Insights

• 🌐 Worldwide Healthcare Trust's success is attributed to its global approach, diverse investment options, and staying ahead of innovation in the healthcare sector.
• 😤 The trust's large investment team, including experts in various fields, gives them a competitive advantage.
• #️⃣ Emerging market names in China and small-cap, unprofitable biotech companies have been key contributors to the trust's recent outperformance.
• 😮 The trust sees Asia, particularly China, as a rising force in the biopharma sector and strategically invests in blue-chip leaders and IPOs.
• 🎁 The COVID-19 pandemic presented buying opportunities for the trust, and healthcare stocks related to testing and treatment performed well.
• 🉐 The trust maintains dry powder to take advantage of market weakness and adjusts its leverage strategically.
• 👋 Market predictions regarding a second wave and future weakness are uncertain, but the trust remains prepared to seize new opportunities.

Questions & Answers

Q: How has Worldwide Healthcare Trust consistently outperformed its benchmark over the past 25 years?

Worldwide Healthcare Trust attributes its outperformance to its global approach to healthcare investing, investing across various sub-sectors, and staying on top of innovation in both public and private healthcare companies. Additionally, the trust's large investment team, comprised of experts in different fields, helps identify the best opportunities.

Q: Which sectors have been the key contributors to the trust's recent outperformance?

In the last fiscal year, emerging market names in China and small-cap, unprofitable biotech companies were the key drivers of the trust's performance. Other sectors, such as medtech, tools and diagnostics, and e-health services, also contributed significantly.

Q: How does Worldwide Healthcare Trust approach investments in emerging markets, particularly China?

Worldwide Healthcare Trust sees Asia, especially China, as a major powerhouse in the biopharma sector. The trust invests in blue chip leaders in the Chinese market and also makes crossover investments in emerging Chinese biotech companies. This strategy has been successful, with IPO cornerstone investments generating significant gains.

Q: Has the COVID-19 pandemic affected Worldwide Healthcare Trust's performance?

The pandemic presented buying opportunities for the trust, especially in blue-chip stocks that were dislocated. The trust added to its positions in healthcare companies such as Gilead Sciences. COVID-19-related stocks, particularly those involved in testing and treatment, also performed well during the crisis.

Summary & Key Takeaways

• Worldwide Healthcare Trust celebrates its 25th birthday and highlights its impressive investment record in the healthcare sector.

• Key sources of outperformance include a worldwide approach to healthcare investing, ability to invest across different sub-sectors, and staying ahead of innovation in both public and private healthcare companies.

• The size of the investment team, with experts in various areas, is the trust's competitive advantage in identifying the best investment opportunities.